Merck (NYSE:MRK) announced this week that its experimental anesthesia reversal drug sugammadex was rejected by the Food and Drug Administration. This isn't the only drug that the big pharma company has failed to get past the FDA this year; its insomnia drug suvorexant was also rejected earlier in 2013. What does this most recent rejection mean for investors, and is Merck making the right changes to its research and development structure? In the following video, a segment from The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss the impact of the FDA's decision.